Recordati signs silodosin deal as sales slow on lercanidipine patent expiry
This article was originally published in Scrip
Executive Summary
Recordati has reported just 1% growth in first-quarter sales, to €186 million, after its key product lercanidipine (marketed as Zanidip) lost its composition of matter patent in the main European countries in January. Pharmaceutical sales rose by 2% to €180 million, with pharmaceutical chemicals down by 10% to €6.2 million.